RT Journal Article
SR Electronic
T1 Dynamics of Hepatitis C Virus Seroprevalence: Evaluating Risk Factors among Sex Workers in Pakistan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.10.19.23297264
DO 10.1101/2023.10.19.23297264
A1 Tirmizi, Raza
A1 Rashid, Rida
A1 Zaidi, Nousheen
YR 2023
UL http://medrxiv.org/content/early/2023/10/26/2023.10.19.23297264.abstract
AB The current study investigates the seroprevalence of the Hepatitis C Virus (HCV) among sex workers in Pakistan, a challenging task due to social and cultural barriers. Our primary objectives were to gauge the extent of HCV exposure in this marginalized group, identify disparities in seroprevalence between sexes, and examine the association between seropositivity and various demographic and risk factors. A total of 1,000 participants were enrolled, with male sex workers comprising the majority (87.7%) and female sex workers accounting for 12.3%. Notably, a significant portion fell within the 26-35 age category (39.9%). A significant proportion (47.1%) had not received formal education. Overall, HCV antibodies were found in 15% of the participants. Disparities were evident, with a seroprevalence of 13% in male sex workers and a significantly higher 31% in female sex workers. HCV seropositivity increased with age, with female sex workers showing a sharper rise. A link between levels of formal education and HCV seroprevalence was observed, with female sex workers consistently exhibiting higher seroprevalence across educational levels. Risk factors such as shaving practices, blade sharing, surgical history, and other medical exposures were assessed, revealing higher HCV seropositivity rates among those exposed, especially pronounced among female participants. This research study paves the way for future investigations and interventions tailored to this population’s unique needs and vulnerabilities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was granted by Bioethics Committee of Cancer Research Center.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files.